.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Argus Health
Harvard Business School
Citi
Healthtrust
Julphar
US Army
Cipla
Merck
Deloitte

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022387

« Back to Dashboard
NDA 022387 describes TYVASO, which is a drug marketed by United Therap and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TYVASO profile page.

The generic ingredient in TYVASO is treprostinil. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the treprostinil profile page.

Summary for NDA: 022387

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1

Pharmacology for NDA: 022387

Ingredient-typeProstaglandins I
Physiological EffectVasodilation

Suppliers and Packaging for NDA: 022387

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TYVASO
treprostinil
SOLUTION;INHALATION 022387 NDA United Therapeutics Corp. 66302-206 66302-206-01 1 BOX in 1 KIT (66302-206-01) > 28 AMPULE in 1 BOX > 2.9 mL in 1 AMPULE
TYVASO
treprostinil
SOLUTION;INHALATION 022387 NDA United Therapeutics Corp. 66302-206 66302-206-02 1 BOX in 1 KIT (66302-206-02) > 28 AMPULE in 1 BOX > 2.9 mL in 1 AMPULE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INHALATIONStrength0.6MG/ML
Approval Date:Jul 30, 2009TE:RLD:Yes
Patent:6,765,117Patent Expiration:Oct 24, 2017Product Flag?Substance Flag?YDelist Request?
Patent:8,497,393Patent Expiration:Dec 15, 2028Product Flag?Substance Flag?YDelist Request?
Patent:9,339,507Patent Expiration:Mar 10, 2028Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 022387

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
United Therap
TYVASO
treprostinil
SOLUTION;INHALATION022387-001Jul 30, 20095,153,222► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Novartis
McKesson
Deloitte
Medtronic
Chinese Patent Office
Fish and Richardson
US Army
Queensland Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot